

Global Lysosomal Storage Disorders (LSDs) Market - 2023-2033

<https://marketpublishers.com/r/G5220EE8BDB8EN.html>

Date: June 2025

Pages: 200

Price: US\$ 2,999.00 (Single User License)

ID: G5220EE8BDB8EN

Abstracts

The Global Lysosomal Storage Disorders (LSDs) Market was valued at US\$ 9.68 Billion in 2023 and is anticipated to reach US\$ 18.18 Billion by 2033, at a CAGR of 0.066 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Lysosomal Storage Disorders (LSDs) Market.

This report delivers a comprehensive overview of the Global Lysosomal Storage Disorders (LSDs) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Lysosomal Storage Disorders (LSDs) Market. The Global Lysosomal Storage Disorders (LSDs) Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.

Global Lysosomal Storage Disorders (LSDs) Market Scope:

Key Players

Sanofi Genzyme

Shire

Alexion Pharmaceuticals, Inc

Johnson & Johnson

Pfizer Inc

Amicus Therapeutics, Inc

JCR Pharmaceuticals Co., Ltd

Ultragenyx Pharmaceutical Inc

Major Highlights

This report delivers a comprehensive overview of the Global Lysosomal Storage Disorders (LSDs) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Lysosomal Storage Disorders (LSDs) Market. The Global Lysosomal Storage Disorders (LSDs) Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions

apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS

- 3.1. Key Trends and Future Projections
- 3.2. Snippet by Disease Type
- 3.3. Snippet by Treatment Type
- 3.4. Snippet by Route of Administration
- 3.5. Snippet by End User
- 3.6. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Increasing Prevalence of Rare Genetic Disorders
 - 4.1.1.2. Advancements in Enzyme Replacement and Gene Therapies
 - 4.1.1.3. Rising Awareness and Early Diagnosis Initiatives
 - 4.1.2. Restraints
 - 4.1.2.1. High Treatment and Therapy Costs
 - 4.1.2.2. Limited Availability of Skilled Professionals
 - 4.1.2.3. Regulatory Challenges and Lengthy Approval Timelines
 - 4.1.3. Opportunity
 - 4.1.3.1. Growth in Gene Therapy and Personalized Medicine
 - 4.1.3.2. Emerging Markets with Improving Healthcare Infrastructure
 - 4.1.3.3. Strategic Collaborations and R&D Investments
 - 4.1.4. Impact Analysis

5. GLOBAL LYSOSOMAL STORAGE DISORDERS (LSDS) MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 5.1. Market Leaders and Pioneers
 - 5.1.1. Emerging Pioneers and Prominent Players
 - 5.1.2. Established leaders with largest largest-selling Brand
 - 5.1.3. Market leaders with established products & Services
- 5.2. Latest Developments and Breakthroughs
- 5.3. Regulatory and Reimbursement Landscape
 - 5.3.1. North America
 - 5.3.2. Europe
 - 5.3.3. Asia Pacific
 - 5.3.4. South America
 - 5.3.5. Middle East & Africa
- 5.4. Porter's Five Force Analysis
- 5.5. Supply Chain Analysis
- 5.6. Patent Analysis
- 5.7. SWOT Analysis
- 5.8. Unmet Needs and Gaps
- 5.9. Recommended Strategies for Market Entry and Expansion
- 5.10. Pricing Analysis and Price Dynamics

6. GLOBAL LYSOSOMAL STORAGE DISORDERS (LSDS) MARKET: BY DISEASE TYPE

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
 - 6.1.2. Market Attractiveness Index, By Disease Type
- 6.2. Gaucher Disease*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Fabry Disease
- 6.4. Pompe Disease
- 6.5. Mucopolysaccharidosis (MPS)
- 6.6. Niemann-Pick Disease
- 6.7. Others

7. GLOBAL LYSOSOMAL STORAGE DISORDERS (LSDS) MARKET: BY TREATMENT TYPE

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

- 7.1.2. Market Attractiveness Index, By Treatment Type
- 7.2. Enzyme Replacement Therapy (ERT)*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Substrate Reduction Therapy (SRT)
- 7.4. Stem Cell Transplantation
- 7.5. Chaperone Therapy
- 7.6. Gene Therapy (Emerging)
- 7.7. Supportive Treatment

8. GLOBAL LYSOSOMAL STORAGE DISORDERS (LSDS) MARKET: BY ROUTE OF ADMINISTRATION

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 8.1.2. Market Attractiveness Index, By Route of Administration
- 8.2. Intravenous*
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Oral
- 8.4. Others

9. GLOBAL LYSOSOMAL STORAGE DISORDERS (LSDS) MARKET: BY END USER

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 9.1.2. Market Attractiveness Index, By End User
- 9.2. Hospitals*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Specialty Clinics
- 9.4. Research Institutes
- 9.5. Home Healthcare

10. GLOBAL LYSOSOMAL STORAGE DISORDERS (LSDS) MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

10.1.1.1. Market Attractiveness Index, By Region

10.2. North America

10.2.1. Introduction

10.2.2. Key Region-Specific Dynamics

10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.2.7.1. U.S.

10.2.7.2. Canada

10.2.7.3. Mexico

10.3. Europe

10.3.1. Introduction

10.3.2. Key Region-Specific Dynamics

10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.3.7.1. Germany

10.3.7.2. U.K.

10.3.7.3. France

10.3.7.4. Spain

10.3.7.5. Italy

10.3.7.6. Rest of Europe

10.4. South America

10.4.1. Introduction

10.4.2. Key Region-Specific Dynamics

10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.4.7.1. Brazil

10.4.7.2. Argentina

10.4.7.3. Rest of South America

10.5. Asia-Pacific

10.5.1. Introduction

10.5.2. Key Region-Specific Dynamics

10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.5.7.1. China

10.5.7.2. India

10.5.7.3. Japan

10.5.7.4. South Korea

10.5.7.5. Rest of Asia-Pacific

10.6. Middle East and Africa

10.6.1. Introduction

10.6.2. Key Region-Specific Dynamics

10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

11.1. Competitive Overview and Key Market Players

11.1.1. Market Share Analysis and Positioning Matrix

11.1.2. Strategic Partnerships, Mergers & Acquisitions

11.1.3. Key Developments in Product Portfolios and Innovations

11.1.4. Company Benchmarking

12. COMPANY PROFILES

12.1. Sanofi Genzyme*

12.1.1. Company Overview

12.1.2. Product Portfolio

- 12.1.2.1. Product Description
- 12.1.2.2. Product Key Performance Indicators (KPIs)
- 12.1.2.3. Historic and Forecasted Product Sales
- 12.1.2.4. Product Sales Volume
- 12.1.3. Financial Overview
 - 12.1.3.1. Company Revenue
 - 12.1.3.2. Geographical Revenue Shares
 - 12.1.3.3. Revenue Forecasts
- 12.1.4. Key Developments
 - 12.1.4.1. Mergers & Acquisitions
 - 12.1.4.2. Key Product Development Activities
 - 12.1.4.3. Regulatory Approvals, etc.
 - 12.1.4.4. SWOT Analysis
- 12.2. Shire
- 12.3. Alexion Pharmaceuticals, Inc
- 12.4. Johnson & Johnson
- 12.5. Pfizer Inc
- 12.6. Amicus Therapeutics, Inc
- 12.7. JCR Pharmaceuticals Co., Ltd
- 12.8. Ultragenyx Pharmaceutical Inc (LIST NOT EXHAUSTIVE)

13. ASSUMPTIONS AND RESEARCH METHODOLOGY

- 13.1. Data Collection Methods
- 13.2. Data Triangulation
- 13.3. Forecasting Techniques
- 13.4. Data Verification and Validation

14. APPENDIX

- 14.1. About Us and Services
- 14.2. Contact Us

I would like to order

Product name: Global Lysosomal Storage Disorders (LSDs) Market - 2023-2033

Product link: <https://marketpublishers.com/r/G5220EE8BDB8EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5220EE8BDB8EN.html>